THE RESULTS OF TREATMENT OF BENIGN PROSTATIC OBSTRUCTION WITH FINASTERIDE
<p align="LEFT"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-L...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Slovenian Medical Association
2001-12-01
|
| Series: | Zdravniški Vestnik |
| Subjects: | |
| Online Access: | http://vestnik.szd.si/index.php/ZdravVest/article/view/2605 |
| Summary: | <p align="LEFT"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;">Background. </span></span></span><em><span style="color: #231f20; font-family: GaramondItcTEE-LighItal; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-LighItal; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-LighItal; font-size: xx-small;">Finasteride is an inhibitor of 5 alpha-</span></span></span></em></p><em><em></em></em><p align="LEFT">reductase. It prevents the conversion of testosterone into</p><em><em></em></em><p align="LEFT">dihydrotestosterone, which results in gradual decrease in prostatic</p><em><em></em></em><p align="LEFT">volume. The objective of the study was to determine the</p><em><em></em></em><p align="LEFT">impact of finasteride on subjective and objective symptomatic</p><em><em></em></em><p align="LEFT">improvement in patients with benign prostatic obstruction</p><em><em></em></em><p align="LEFT">(BPO).</p><em></em><p align="LEFT"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><br /></span></span></span></p><p align="LEFT"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;">P</span></span></span><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;">atients and methods. </span></span></span><em><span style="color: #231f20; font-family: GaramondItcTEE-LighItal; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-LighItal; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-LighItal; font-size: xx-small;">This open prospective multicenter study</span></span></span></em></p><em><em></em></em><p align="LEFT">of 6-month duration included 370 men, mean age 63 years</p><em><em></em></em><p align="LEFT">(range; 45–75 yrs), with clinical manifestations of BPO. The</p><em><em></em></em><p align="LEFT">enrolled patients received finasteride 5 mg/day. On the completion</p><em><em></em></em><p align="LEFT">of therapy, the patients were assessed for symptomatic</p><em><em></em></em><p align="LEFT">improvement, urinary flow and prostatic volume, determined</p><em><em></em></em><p align="LEFT">by rectal examination and ultrasound. Total prostate-specific</p><em><em></em></em><p align="LEFT">antigen levels in the serum were measured. At the end of the</p><em><em></em></em><p align="LEFT">study, the patients were asked to evaluate the efficacy of finasteride</p><em><em></em></em><p align="LEFT">therapy and to report its possible adverse side-effects.</p><em><em></em></em><p align="LEFT">Statistical analysis of the results was done using the Student ttest.</p><em></em><p align="LEFT"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><br /></span></span></span></p><p align="LEFT"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;">Results. </span></span></span><em><span style="color: #231f20; font-family: GaramondItcTEE-LighItal; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-LighItal; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-LighItal; font-size: xx-small;">Of the 370 patients enrolled, 303 (82%) completed the</span></span></span></em></p><em><em></em></em><p align="LEFT">6-month study period. The rate of urinary symptoms declined</p><em><em></em></em><p align="LEFT">by an average of 55%, of which nocturia by 28% and difficulty</p><em><em></em></em><p align="LEFT">in initiating the urinary stream by 74%. There was a</p><em><em></em></em><p align="LEFT">statistically significant decrease in prostatic volume on rectal</p><em><em></em></em><p align="LEFT">examination (14%; p < 0.0001) and abdominal ultrasound</p><em><em></em></em><p align="LEFT">(16%; p < 0.0037). The difference between both measurements</p><em><em></em></em><p align="LEFT">was statistically significant (p = 0.0037). Finasteride produced</p><em><em></em></em><p align="LEFT">a statistically significant improvement in maximum urinary</p><em><em></em></em><p align="LEFT">flow rate and voiding time (p < 0.0001 and p = 0.0017,</p><em><em></em></em><p align="LEFT">respectively). Untoward side-effects were experienced by 3.5%</p><em><em></em></em><p align="LEFT">of the patients who had completed the 6-month period of finasteride</p><em><em></em></em><p align="LEFT">therapy. A the end of the study, 65% of the patients</p><em><em></em></em><p align="LEFT">reported notable improvement in micturition, and 76% stated</p><em><em></em></em><p align="LEFT">they would continue taking finasteride.</p><em></em><p align="LEFT"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><br /></span></span></span></p><p align="LEFT"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-Ligh; font-size: xx-small;">Conclusion. </span></span></span><em><span style="color: #231f20; font-family: GaramondItcTEE-LighItal; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-LighItal; font-size: xx-small;"><span style="color: #231f20; font-family: GaramondItcTEE-LighItal; font-size: xx-small;">Placing patients with urinary symptoms due to</span></span></span></em></p><em><em></em></em><p align="LEFT">BPO on a 6-month course of finasteride has proved safe and</p><em><em></em></em><p>effective.</p><em></em> |
|---|---|
| ISSN: | 1318-0347 1581-0224 |